Lung transplantation: advances in immunosuppression.


Journal Article (Review)

Since the advent of various novel immunosuppressants, including tacrolimus, rapamycin, and daclixumab. expanding variations of protocols have been developed. Little evidence exists to substantially support a single agent over another. or a combination regimen protocol over another. Therefore, the principles and the goals of immunosuppression in lung transplantation recipients will remain moving targets and continue to evolve, and the use of large-scale, multi-institutional clinical trials is imperative to develop optimal immunosuppressive strategies.

Full Text

Duke Authors

Cited Authors

  • Bush, EL; Lin, SS

Published Date

  • November 2006

Published In

Volume / Issue

  • 16 / 4

Start / End Page

  • 421 - 433

PubMed ID

  • 17240827

Pubmed Central ID

  • 17240827

International Standard Serial Number (ISSN)

  • 1547-4127

Digital Object Identifier (DOI)

  • 10.1016/j.thorsurg.2006.07.002


  • eng

Conference Location

  • United States